Completion of the pharmacokinetics study of AD04 enables the end-of-Phase 2 (EOP2) interaction with the FDA, a crucial step toward advancing to Phase 3 trials. Study results support the planned ...
three-phase investigational new drug process (Phase I: establish drug safety and pharmacokinetics; Phase II: establish therapeutic efficacy and dosage range; Phase III: comparative clinical trials ...
Aims Clopidogrel is the most commonly prescribed thienopyridine as part of dual anti-platelet therapy for the treatment of ...
AnaptysBio (ANAB) announced statistically significant Week 12 data from the global 424-patient Phase 2b RENOIR trial of investigational ...
Study completion enables an End-of-Phase 2 FDA meeting and strengthens ... ADIL announced the completion of the AD04-103 pharmacokinetics (PK) study for AD04, confirming predictable ...
Third Harmonic Bio (THRD) announced results from its Phase 1 single and multiple ascending dose clinical trial of THB335 in healthy volunteers.
“The human PK model of GD2-SADA informed the design and initial dosing regimen of our ongoing first-in-human (FIH) Phase 1 Trial (Trial 1001),” said Norman LaFrance, M.D., Chief Development Officer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback